Elelyso taliglucerase alfa regulatory update

FDA approved an sNDA from Pfizer for Elelyso taliglucerase alfa as long-term enzyme replacement therapy for pediatric patients with Type 1 Gaucher's disease. The plant cell-expressed recombinant form ...